SMA in Adults: Interim Data Back Nusinersen Efficacy
New trial focuses on drug's performance in spinal muscular atrophy beyond childhood
Source: medpagetoday.com
Page 2 - Revised Upper Limb Module News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Revised Upper Limb Module. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Revised Upper Limb Module Today - Breaking & Trending Today
New Four-Year Data for Genentech's Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Seite 1
20.03.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data ... Seite 1
Source: wallstreet-online.de
F. Hoffmann-La Roche Ltd: New four year data for Roche's Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease
Source: finanznachrichten.de
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play
Source: finanznachrichten.de
Nusinersen May Stabilize Disease Status in SMA Types 2 and 3
Treatment with nusinersen may decrease disease progression in pediatric patients who are nonambulatory with spinal muscular atrophy types 2 and 3.
Source: neurologyadvisor.com